Comunicazione AIFA su Barbesaclone

Asset Publisher

Comunicazione AIFA su Barbesaclone

Nuove e importanti informazioni relative alla produzione e alla distribuzione del medicinale a denominazione generica Barbesaclone 25 mg compresse rivestite - PROROGA SCADENZA.

Published on: 09 dicembre 2019

Asset Publisher

Site Map

Quality and Inspections

Share

Nested Applications

Highlights

30/12/2024 - AIFA President Nisticò: “With the approval of the single role for scientific officers, high-profile professionals who are strategic for the proper functioning of the Agency are secured”

16/12/2024 - AIFA launches crackdown on conflict of interest. But opens the way for free opinions and consultations by high-profile professionals

ALL NEWS

News

27/12/2024

Available the English version of the 2023 National Report on "National report on medicines use in Italy"

24/12/2024

Hepatitis C: update of 23 December 2024 concerning enrolled patients

18/12/2024

Message of the Minister of Health Orazio Schillaci to AIFA

All news

Galleria

Nested Applications

Press

AIFA President Nisticò: “With the approval of the single role for scientific officers, high-profile professionals who are strategic for the proper functioning of the Agency are secured”

Aifa toggle bar Search

Aifa toggle bar Search

Comunicazione AIFA su Barbesaclone - Comunicazione AIFA su Barbesaclone

Asset Publisher

Asset Publisher

Comunicazione AIFA su Barbesaclone

Asset Publisher

Related documents

Site Map

Quality and Inspections

Share

Nested Applications

Highlights

30/12/2024 - AIFA President Nisticò: “With the approval of the single role for scientific officers, high-profile professionals who are strategic for the proper functioning of the Agency are secured”

16/12/2024 - AIFA launches crackdown on conflict of interest. But opens the way for free opinions and consultations by high-profile professionals

ALL NEWS

News

Galleria

Nested Applications

Press

AIFA President Nisticò: “With the approval of the single role for scientific officers, high-profile professionals who are strategic for the proper functioning of the Agency are secured”

All press releases

Last tweets

Go to Twitter profile

Go to Twitter profile

Multimedia

Spot 2024

Go to YouTube channel

Cookie Bar

Descrizione cookieBar

Footer

The agency

Contacts

FOLLOW US ON

FEED RSS

COOKIES

Language Selector

Language Selector

Aifa toggle bar Search

Comunicazione AIFA su Barbesaclone - Comunicazione AIFA su Barbesaclone

Breadcrumb

Asset Publisher

Asset Publisher

Comunicazione AIFA su Barbesaclone

Asset Publisher

Related documents

Site Map

Quality and Inspections

Share

Nested Applications

Highlights

30/12/2024 - AIFA President Nisticò: “With the approval of the single role for scientific officers, high-profile professionals who are strategic for the proper functioning of the Agency are secured”

16/12/2024 - AIFA launches crackdown on conflict of interest. But opens the way for free opinions and consultations by high-profile professionals

ALL NEWS

News

Galleria

Nested Applications

Press

AIFA President Nisticò: “With the approval of the single role for scientific officers, high-profile professionals who are strategic for the proper functioning of the Agency are secured”

All press releases

Last tweets

Go to Twitter profile

Go to Twitter profile aifa_ufficiale

Multimedia

Spot 2024

Go to YouTube channel

Cookie Bar

cookie management module

Descrizione cookieBar

Footer

The agency

Contacts

FOLLOW US ON

FEED RSS

COOKIES

Sezione Link Utili

Go to Twitter profile